 | • レポートコード：MRC2301F0007 • 出版社/出版日：Transparency Market Research / 2022年11月24日 • レポート形態：英文、PDF、250ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| トランスペアレンシー・マーケット・リサーチ社の当調査資料では、世界の間葉系幹細胞市場について総合的に調査・分析を行い、エグゼクティブサマリー、市場概要、市場背景、コンポーネント別（製品、サービス）分析、種類別（自己、同種異系）分析、分離元別（骨髄、臍帯血、末梢血、卵管、その他）分析、疾患別（骨・軟骨修復、循環器疾患、炎症・免疫疾患、肝疾患、その他）分析、地域別（北米、中南米、ヨーロッパ、アジア太平洋、中東/アフリカ）分析、競争状況、企業情報などの項目を掲載しています。なお、当市場の主要企業には、Thermo Fisher Scientific、Cell Applications, Inc.、Cyagen Biosciences、Axol Biosciences Ltd.、Cytori Therapeutics Inc.、Stemcell Technologies Inc、Celprogen Inc、Brainstorm Cell Therapeutics Inc、Stemedica Cell Technologies, Inc.、Merck Milliporeなどが含まれています。 ・エグゼクティブサマリー ・市場概要 ・市場背景 ・世界の間葉系幹細胞市場規模：コンポーネント別 - 製品の市場規模 - サービスの市場規模 ・世界の間葉系幹細胞市場規模：種類別 - 自己間葉系幹細胞の市場規模 - 同種異系間葉系幹細胞の市場規模 ・世界の間葉系幹細胞市場規模：分離元別 - 骨髄の市場規模 - 臍帯血の市場規模 - 末梢血の市場規模 - 卵管の市場規模 - その他分離元の市場規模 ・世界の間葉系幹細胞市場規模：疾患別 - 骨・軟骨修復の市場規模 - 循環器疾患の市場規模 - 炎症・免疫疾患の市場規模 - 肝疾患の市場規模 - その他疾患の市場規模 ・世界の間葉系幹細胞市場規模：地域別 - 北米の間葉系幹細胞市場規模 - ヨーロッパの間葉系幹細胞市場規模 - アジア太平洋の間葉系幹細胞市場規模 - 中東/アフリカの間葉系幹細胞市場規模 ・競争状況 ・企業情報 |
Mesenchymal Stem Cells Market – Scope of Report
TMR’s report on the global mesenchymal stem cells market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global mesenchymal stem cells market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global mesenchymal stem cells market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the mesenchymal stem cells market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global mesenchymal stem cells market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global mesenchymal stem cells market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global mesenchymal stem cells market.
The report delves into the competitive landscape of the global mesenchymal stem cells market. Key players operating in the global mesenchymal stem cells market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global mesenchymal stem cells market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market mesenchymal stem cells.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
レポート目次1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. Value Chain Analysis
3.5.1. Profit Margin Analysis
3.5.2. Service Providers
3.6. PESTLE and Porter’s Analysis
3.7. Regulatory Landscape
3.7.1. By Key Regions
3.7.2. By Key Countries
3.8. Regional Parent Market Outlook
4. Global Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Bn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Bn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Component
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Bn) Analysis By Component, 2017-2021
5.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Component, 2022-2032
5.3.1. Product
5.3.1.1. Workflow Type
5.3.1.2. Product Type
5.3.2. Service
5.4. Y-o-Y Growth Trend Analysis By Component, 2017-2021
5.5. Absolute $ Opportunity Analysis By Component, 2022-2032
6. Global Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Bn) Analysis By Type, 2017-2021
6.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Type, 2022-2032
6.3.1. Autologous
6.3.2. Allogeneic
6.4. Y-o-Y Growth Trend Analysis By Type, 2017-2021
6.5. Absolute $ Opportunity Analysis By Type, 2022-2032
7. Global Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Source of Isolation
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Bn) Analysis By Source of Isolation, 2017-2021
7.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Source of Isolation, 2022-2032
7.3.1. Bone Marrow
7.3.2. Cord Blood
7.3.3. Peripheral Blood
7.3.4. Fallopian Tube
7.3.5. Fetal Liver
7.3.6. Lung
7.3.7. Adipose Tissues
7.4. Y-o-Y Growth Trend Analysis By Source of Isolation, 2017-2021
7.5. Absolute $ Opportunity Analysis By Source of Isolation, 2022-2032
8. Global Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Indication
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Bn) Analysis By Indication , 2017-2021
8.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Indication , 2022-2032
8.3.1. Bone And Cartilage Repair
8.3.2. Cardiovascular Disease
8.3.3. Inflammatory And Immunological Diseases
8.3.4. Liver Diseases
8.3.5. Cancer
8.3.6. GvHD
8.3.7. Other Indications
8.4. Y-o-Y Growth Trend Analysis By Indication , 2017-2021
8.5. Absolute $ Opportunity Analysis By Indication , 2022-2032
9. Global Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Bn) Analysis By Region, 2017-2021
9.3. Current Market Size Value (US$ Bn) Analysis and Forecast By Region, 2022-2032
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. Asia Pacific
9.3.5. MEA
9.4. Market Attractiveness Analysis By Region
10. North America Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Value (US$ Bn)ed States
10.2.1.2. Canada
10.2.2. By Component
10.2.3. By Type
10.2.4. By Source of Isolation
10.2.5. By Indication
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Component
10.3.3. By Type
10.3.4. By Source of Isolation
10.3.5. By Indication
10.4. Key Takeaways
11. Latin America Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Component
11.2.3. By Type
11.2.4. By Source of Isolation
11.2.5. By Indication
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Component
11.3.3. By Type
11.3.4. By Source of Isolation
11.3.5. By Indication
11.4. Key Takeaways
12. Europe Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. U.K.
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Russia
12.2.1.7. Rest of Europe
12.2.2. By Component
12.2.3. By Type
12.2.4. By Source of Isolation
12.2.5. By Indication
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Component
12.3.3. By Type
12.3.4. By Source of Isolation
12.3.5. By Indication
12.4. Key Takeaways
13. Asia Pacific Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. India
13.2.1.4. South Korea
13.2.1.5. Australia
13.2.1.6. Rest of APAC
13.2.2. By Component
13.2.3. By Type
13.2.4. By Source of Isolation
13.2.5. By Indication
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Component
13.3.3. By Type
13.3.4. By Source of Isolation
13.3.5. By Indication
13.4. Key Takeaways
14. MEA Mesenchymal Stem Cells Market Analysis 2017-2021 and Forecast 2022-2032, By Country
14.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
14.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
14.2.1. By Country
14.2.1.1. South Africa
14.2.1.2. Saudi Arabia
14.2.1.3. UAE
14.2.1.4. Israel
14.2.1.5. Rest of MEA
14.2.2. By Component
14.2.3. By Type
14.2.4. By Source of Isolation
14.2.5. By Indication
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Component
14.3.3. By Type
14.3.4. By Source of Isolation
14.3.5. By Indication
14.4. Key Takeaways
15. Key Countries Mesenchymal Stem Cells Market Analysis
15.1. Value (US$ Bn)ed States
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2021
15.1.2.1. By Component
15.1.2.2. By Type
15.1.2.3. By Source of Isolation
15.1.2.4. By Indication
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2021
15.2.2.1. By Component
15.2.2.2. By Type
15.2.2.3. By Source of Isolation
15.2.2.4. By Indication
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2021
15.3.2.1. By Component
15.3.2.2. By Type
15.3.2.3. By Source of Isolation
15.3.2.4. By Indication
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2021
15.4.2.1. By Component
15.4.2.2. By Type
15.4.2.3. By Source of Isolation
15.4.2.4. By Indication
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2021
15.5.2.1. By Component
15.5.2.2. By Type
15.5.2.3. By Source of Isolation
15.5.2.4. By Indication
15.6. U.K.
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2021
15.6.2.1. By Component
15.6.2.2. By Type
15.6.2.3. By Source of Isolation
15.6.2.4. By Indication
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2021
15.7.2.1. By Component
15.7.2.2. By Type
15.7.2.3. By Source of Isolation
15.7.2.4. By Indication
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2021
15.8.2.1. By Component
15.8.2.2. By Type
15.8.2.3. By Source of Isolation
15.8.2.4. By Indication
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2021
15.9.2.1. By Component
15.9.2.2. By Type
15.9.2.3. By Source of Isolation
15.9.2.4. By Indication
15.10. Russia
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2021
15.10.2.1. By Component
15.10.2.2. By Type
15.10.2.3. By Source of Isolation
15.10.2.4. By Indication
15.11. China
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2021
15.11.2.1. By Component
15.11.2.2. By Type
15.11.2.3. By Source of Isolation
15.11.2.4. By Indication
15.12. Japan
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2021
15.12.2.1. By Component
15.12.2.2. By Type
15.12.2.3. By Source of Isolation
15.12.2.4. By Indication
15.13. India
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2021
15.13.2.1. By Component
15.13.2.2. By Type
15.13.2.3. By Source of Isolation
15.13.2.4. By Indication
15.14. South Korea
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2021
15.14.2.1. By Component
15.14.2.2. By Type
15.14.2.3. By Source of Isolation
15.14.2.4. By Indication
15.15. Australia
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2021
15.15.2.1. By Component
15.15.2.2. By Type
15.15.2.3. By Source of Isolation
15.15.2.4. By Indication
15.16. South Africa
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2021
15.16.2.1. By Component
15.16.2.2. By Type
15.16.2.3. By Source of Isolation
15.16.2.4. By Indication
15.17. Saudi Arabia
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2021
15.17.2.1. By Component
15.17.2.2. By Type
15.17.2.3. By Source of Isolation
15.17.2.4. By Indication
15.18. UAE
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2021
15.18.2.1. By Component
15.18.2.2. By Type
15.18.2.3. By Source of Isolation
15.18.2.4. By Indication
15.19. Israel
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2021
15.19.2.1. By Component
15.19.2.2. By Type
15.19.2.3. By Source of Isolation
15.19.2.4. By Indication
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Component
16.3.3. By Type
16.3.4. By Source of Isolation
16.3.5. By Indication
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Thermo Fisher Scientific
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.1.5.2. Product Strategy
17.1.1.5.3. Channel Strategy
17.1.2. Cell Applications, Inc.
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.2.5.2. Product Strategy
17.1.2.5.3. Channel Strategy
17.1.3. Cyagen Biosciences
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.3.5.2. Product Strategy
17.1.3.5.3. Channel Strategy
17.1.4. Axol Biosciences Ltd.
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.4.5.2. Product Strategy
17.1.4.5.3. Channel Strategy
17.1.5. Cytori Therapeutics Inc.
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.5.5.2. Product Strategy
17.1.5.5.3. Channel Strategy
17.1.6. Stemcell Technologies Inc
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.6.5.2. Product Strategy
17.1.6.5.3. Channel Strategy
17.1.7. Celprogen Inc
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.7.5.2. Product Strategy
17.1.7.5.3. Channel Strategy
17.1.8. Brainstorm Cell Therapeutics Inc
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.8.5.2. Product Strategy
17.1.8.5.3. Channel Strategy
17.1.9. Stemedica Cell Technologies, Inc.
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.9.5.2. Product Strategy
17.1.9.5.3. Channel Strategy
17.1.10. Merck Millipore
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.10.5.2. Product Strategy
17.1.10.5.3. Channel Strategy
17.1.11. Smith & Nephew
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.11.5.2. Product Strategy
17.1.11.5.3. Channel Strategy
17.1.12. Lonza AG
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
17.1.12.5.2. Product Strategy
17.1.12.5.3. Channel Strategy
17.1.13. PromoCell GMBH
17.1.13.1. Overview
17.1.13.2. Product Portfolio
17.1.13.3. Profitability by Market Segments
17.1.13.4. Sales Footprint
17.1.13.5. Strategy Overview
17.1.13.5.1. Marketing Strategy
17.1.13.5.2. Product Strategy
17.1.13.5.3. Channel Strategy
17.1.14. Sciencell Research Laboratories
17.1.14.1. Overview
17.1.14.2. Product Portfolio
17.1.14.3. Profitability by Market Segments
17.1.14.4. Sales Footprint
17.1.14.5. Strategy Overview
17.1.14.5.1. Marketing Strategy
17.1.14.5.2. Product Strategy
17.1.14.5.3. Channel Strategy
17.1.15. American Type Culture Collection
17.1.15.1. Overview
17.1.15.2. Product Portfolio
17.1.15.3. Profitability by Market Segments
17.1.15.4. Sales Footprint
17.1.15.5. Strategy Overview
17.1.15.5.1. Marketing Strategy
17.1.15.5.2. Product Strategy
17.1.15.5.3. Channel Strategy
18. Assumptions & Acronyms Used
19. Research Methodology